COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network

Charlotte Lanièce Delaunay(Helicon Foundation), Esther Kissling, Héloïse Lucaccioni, Mariëtte Hooiveld(Netherlands Institute for Health Services Research), Mihaela Lazăr, Lisa Domegan(Health Service Executive), Marlena Kaczmarek(European Centre for Disease Prevention and Control), Shirley Masse(Inserm), Nuno Verdasca(National Institute of Health Dr. Ricardo Jorge), Gergő Túri(Semmelweis University), Susana Monge(Instituto de Salud Carlos III), Vítor Borges(National Institute of Health Dr. Ricardo Jorge), Ana Paula Rodrigues(Microsoft (Brazil)), Vincent Enouf(Université Claude Bernard Lyon 1), Adam Meijer(National Centre for Infectious Diseases), Ralf Dürrwald(IDT Biologika (Germany)), Sabrina Bacci(European Centre for Disease Prevention and Control), Charlene Bennett(University College Dublin), Neus Latorre‐Margalef(Public Health Agency of Sweden), Noémie Sève(Inserm), Iván Martínez‐Baz(Instituto de Salud Carlos III), Adele McKenna(Health Protection Surveillance Centre), Annika Erdwiens(Robert Koch Institute), Eline In‘t Velt(National Institute for Public Health and the Environment), Ma Ángel Valcárcel de Laiglesia(Regional Health), Ivan Mlinarić(Hrvatski zavod za javno zdravstvo), Miriam López Torrijos(Generalitat Valenciana), Silke Buda(Robert Koch Institute)
SSRN Electronic Journal
January 1, 2025
Cited by 0


Related Papers